Leon Moulder, Jr. Acquires 20,000 Shares of Zenas BioPharma (NASDAQ:ZBIO) Stock

Zenas BioPharma, Inc. (NASDAQ:ZBIO) CEO Leon Moulder, Jr. purchased 20,000 shares of the business’s stock in a transaction on Friday, January 9th. The shares were acquired at an average price of $16.55 per share, for a total transaction of $331,000.00. Following the completion of the acquisition, the chief executive officer directly owned 366,155 shares in the company, valued at approximately $6,059,865.25. This represents a 5.78% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Zenas BioPharma Stock Performance

Shares of ZBIO stock opened at $16.08 on Friday. The firm has a 50 day moving average of $34.94 and a 200-day moving average of $24.11. The company has a market cap of $863.17 million, a price-to-earnings ratio of -2.27 and a beta of -1.45. The company has a quick ratio of 5.66, a current ratio of 5.66 and a debt-to-equity ratio of 0.37. Zenas BioPharma, Inc. has a 52 week low of $5.83 and a 52 week high of $44.60.

Zenas BioPharma (NASDAQ:ZBIO) last issued its earnings results on Wednesday, November 12th. The company reported ($1.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.87) by ($0.35).

Trending Headlines about Zenas BioPharma

Here are the key news stories impacting Zenas BioPharma this week:

• Positive Sentiment: CEO insider purchases — Leon Moulder Jr. bought a total of ~100,000 shares across Jan. 7–9 (50k @ $16.38, 30k @ $16.30, 20k @ $16.55), spending roughly $1.63M and raising his direct stake to ~366,155 shares (~$6.06M value). Large, repeated CEO buys often signal management confidence and can attract buying interest. Zenas Biopharma (ZBIO) CEO Moulder buys $1.63m in stock
• Positive Sentiment: Analyst backdrop is constructive — brokerages’ consensus rating sits at “Moderate Buy” with several buy/outperform opinions and elevated average price targets, which can support demand if sentiment persists. Zenas BioPharma Given Consensus Recommendation of “Moderate Buy”
• Neutral Sentiment: SEC filings confirm timing and price — multiple Form 4 disclosures document the CEO’s transactions, providing transparency on cost basis and validating the insider activity for investors doing due diligence. SEC filing confirming insider purchases
• Neutral Sentiment: Mixed analyst and price‑target dispersion — while many firms are bullish, some recent revisions (e.g., Morgan Stanley trimming its target) create varied upside expectations that can mute a clear consensus move. MarketBeat ZBIO analyst summary
• Negative Sentiment: Litigation/investigation headline risk — Pomerantz LLP issued an investor alert investigating Zenas, which can trigger short‑term volatility, legal costs, and investor caution until the scope and findings are clarified. Pomerantz investigates Zenas BioPharma

Institutional Trading of Zenas BioPharma

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Federated Hermes Inc. raised its stake in shares of Zenas BioPharma by 60.8% in the second quarter. Federated Hermes Inc. now owns 1,861,838 shares of the company’s stock worth $18,041,000 after purchasing an additional 703,838 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Zenas BioPharma by 17.2% during the third quarter. Vanguard Group Inc. now owns 1,162,758 shares of the company’s stock valued at $25,813,000 after buying an additional 170,546 shares during the last quarter. Invesco Ltd. bought a new stake in Zenas BioPharma during the third quarter worth $3,237,000. Millennium Management LLC purchased a new stake in Zenas BioPharma in the 3rd quarter valued at $1,595,000. Finally, Geode Capital Management LLC raised its position in Zenas BioPharma by 4.6% in the 2nd quarter. Geode Capital Management LLC now owns 373,617 shares of the company’s stock valued at $3,621,000 after buying an additional 16,461 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. Morgan Stanley downgraded Zenas BioPharma from an “overweight” rating to an “equal weight” rating and dropped their price target for the stock from $37.00 to $19.00 in a research note on Monday, January 5th. Citigroup raised their price objective on Zenas BioPharma from $27.00 to $46.00 and gave the company a “buy” rating in a research note on Tuesday, October 28th. HC Wainwright reaffirmed a “buy” rating on shares of Zenas BioPharma in a research report on Tuesday, December 16th. Evercore ISI assumed coverage on Zenas BioPharma in a report on Wednesday, November 26th. They issued an “outperform” rating and a $55.00 target price on the stock. Finally, Wall Street Zen downgraded shares of Zenas BioPharma from a “hold” rating to a “sell” rating in a research report on Saturday. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $43.14.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.